<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01633242</url>
  </required_header>
  <id_info>
    <org_study_id>120090</org_study_id>
    <secondary_id>12-H-0090</secondary_id>
    <nct_id>NCT01633242</nct_id>
  </id_info>
  <brief_title>Heart Imaging in Children With Muscular Dystrophy</brief_title>
  <official_title>A Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Muscular dystrophy can affect the muscles used for heart function and breathing. Treatment&#xD;
      usually involves drugs that help improve heart function. However, better types of heart&#xD;
      imaging studies are needed to improve treatment of heart problems related to muscular&#xD;
      dystrophy. Better heart imaging methods are especially needed for children with muscular&#xD;
      dystrophy. Researchers want to test different heart imaging methods in children with muscular&#xD;
      dystrophy. They will look at cardiac magnetic resonance imaging (MRI) and standard heart&#xD;
      function tests.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To develop and test new methods for imaging the heart in children with muscular dystrophy.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Children and adolescents between 8 and 17 years of age who have muscular dystrophy.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history.&#xD;
&#xD;
        -  Participants will provide a blood sample at the start of the study. They will also have&#xD;
           heart function tests before having the imaging study.&#xD;
&#xD;
        -  Participants will have a cardiac MRI scan that will last up to 60 minutes. Some tests&#xD;
           will require a MRI contrast agent (a drug that helps the image appear more clearly on&#xD;
           the scan).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiomyopathy causes significant morbidity and mortality in multiple forms of muscular&#xD;
      dystrophy affecting children, including Duchenne muscular dystrophy (DMD), Becker muscular&#xD;
      dystrophy (BMD) and subtypes of autosomal recessive limb-girdle muscular dystrophy (LGMD2).&#xD;
      Pharmaceutical treatments for the cardiomyopathy of muscular dystrophy, including&#xD;
      angiotensin-converting enzyme (ACE) inhibition and beta-adrenergic receptor blockade, afford&#xD;
      significant benefit and demonstrate cardiac remodeling in clinical studies. Further studies&#xD;
      are needed to identify and characterize more sensitive indicators of cardiac dysfunction in&#xD;
      muscular dystrophy subjects to better stratify subjects for entry into clinical protocols.&#xD;
      Using the framework of the Cooperative International Neuromuscular Research Group (CINRG) and&#xD;
      the Clinical and Translational Science Award (CTSA) consortium, this pilot study will assess&#xD;
      cardiac outcome measures in children obtained by gadolinium enhanced cardiac Magnetic&#xD;
      Resonance Imaging (MRI) and echocardiographic methods that can be reliably implemented across&#xD;
      a consortium of clinical sites devoted to the study of pharmaceutical treatments for muscular&#xD;
      dystrophy. These cardiac MRI scans will be shared with the PITT1109 research protocol in all&#xD;
      subjects that are enrolled in both studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 24, 2012</start_date>
  <completion_date>October 11, 2016</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate CMR measures in muscular dystrophy patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Detection</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Disease Progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultimate identification of the response to developing therapies</measure>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Muscular Dystrophy</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Male or females with a diagnosis of Duchenne, Becker, or Limb Girdle Muscular&#xD;
             Dystrophy.&#xD;
&#xD;
          -  8 to 100 years of age.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Day-time users of continuous positive airway pressure (CPAP)&#xD;
&#xD;
          -  Sip ventilator users&#xD;
&#xD;
          -  Invasive ventilator dependent&#xD;
&#xD;
          -  Pregnant minors (when uncertain, participants will undergo urine testing) or lactating&#xD;
             minors&#xD;
&#xD;
          -  Decompensated congestive heart failure (unable to lie flat during CMR)&#xD;
&#xD;
          -  Impaired renal excretory function (calculated Glomerular Filtration Rate less than&#xD;
             30mL/min)&#xD;
&#xD;
          -  Contra-indications to Magnetic Resonance Imaging:&#xD;
&#xD;
               -  Cardiac pacemaker or implantable defibrillator&#xD;
&#xD;
               -  Cerebral aneurysm clip&#xD;
&#xD;
               -  Neural stimulator&#xD;
&#xD;
               -  Metallic ocular foreign body&#xD;
&#xD;
               -  Harrington-rod&#xD;
&#xD;
               -  Any implanted device (i.e. insulin pump, drug infusion device)&#xD;
&#xD;
               -  Claustrophobia&#xD;
&#xD;
               -  Metal shrapnel or bullet&#xD;
&#xD;
          -  Investigator assessment of inability to comply with protocol&#xD;
&#xD;
          -  Unable/unwilling to lie still throughout the research procedure or who require&#xD;
             sedation&#xD;
&#xD;
          -  Persons with cognitive impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew E Arai, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987 Dec 24;51(6):919-28.</citation>
    <PMID>3319190</PMID>
  </reference>
  <reference>
    <citation>Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990 Mar;26(3):271-7.</citation>
    <PMID>2312196</PMID>
  </reference>
  <reference>
    <citation>Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia-Manzillo G, Tagliagambe LM, Spata M, Santarone M. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol. 2002 Apr 1;89(7):838-41.</citation>
    <PMID>11909570</PMID>
  </reference>
  <verification_date>October 11, 2016</verification_date>
  <study_first_submitted>June 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>Muscular Dystrophy</keyword>
  <keyword>Cardiac</keyword>
  <keyword>Myocardium</keyword>
  <keyword>Intramyocardial fat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

